Active	Status	Sponsor type	Region	Phase	Filter
2 Active 0 Inactive 2 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « July » « 2025 » M T W T F S S 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3   - « July » « 2025 » M T W T F S S 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3   Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Foltynie, Tom
Exenatide-PD3, NCT04232969 / 2018-003028-35: Exenatide Once Weekly Over 2 Years as a Potential Disease Modifying Treatment for Parkinson's Disease	Active, not recruiting	3	194	Europe	Exenatide extended release 2mg (Bydureon)	University College, London, National Institute for Health Research -Efficacy and Mechanism Evaluation Programme	Parkinson's Disease	02/24	07/24
NCT04431713 / 2020-000122-26: Exenatide Once-weekly as a Treatment for Multiple System Atrophy	Completed	2	50	Europe	Exenatide Pen Injector [Bydureon]	University College, London	Multiple System Atrophy	03/24	03/24

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Foltynie, Tom
Exenatide-PD3, NCT04232969 / 2018-003028-35: Exenatide Once Weekly Over 2 Years as a Potential Disease Modifying Treatment for Parkinson's Disease	Active, not recruiting	3	194	Europe	Exenatide extended release 2mg (Bydureon)	University College, London, National Institute for Health Research -Efficacy and Mechanism Evaluation Programme	Parkinson's Disease	02/24	07/24
NCT04431713 / 2020-000122-26: Exenatide Once-weekly as a Treatment for Multiple System Atrophy	Completed	2	50	Europe	Exenatide Pen Injector [Bydureon]	University College, London	Multiple System Atrophy	03/24	03/24